LOS ANGELES, June 25 (Reuters) - Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback